VivoSim regains Nasdaq equity compliance; cash $10.1M; guides 500%+ revenue growth in FY2027

VivoSim Labs, INC.

Regained Nasdaq compliance (Rule 5550(b)(1)) after $5M Eli Lilly milestone and $4M financing.
Cash on hand as of Aug 3, 2026: ~$10.1M, reflecting recent inflows.
Reiterates FY2027 guidance of 500%+ revenue growth from NAMs contract research services.
Share count rose from 3.2M (June 30) to 13.4M (Aug 3) on warrant exercises.
Received $5M milestone from Eli Lilly, $1M escrow release, and $4M gross proceeds financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.